المؤلفون: Clamp AR; Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, UK., James EC; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK. Electronic address: e.james@ucl.ac.uk., McNeish IA; Department of Surgery and Cancer, Imperial College London, London, UK., Dean A; Oncology Department, St John of God Hospital, Subiaco, WA, Australia., Kim JW; Department of Obstetrics and Gynaecology, Seoul National University, Seoul, Korea., O'Donnell DM; Cancer Trials Ireland, Dublin, Ireland., Hook J; St James' University Hospital, Leeds, UK., Coyle C; Queen Alexandra Hospital, Portsmouth Hospitals National Health Service Trust, Portsmouth, UK., Blagden S; Churchill Hospital, University of Oxford, Oxford, UK., Brenton JD; Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Cambridge, UK., Naik R; Gynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK., Perren T; St James' University Hospital, Leeds, UK., Sundar S; Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK., Cook AD; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK., Gopalakrishnan GS; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK., Gabra H; Department of Surgery and Cancer, Imperial College London, London, UK; Early Clinical Development, AstraZeneca, Cambridge, UK., Lord R; Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK., Dark G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK., Earl HM; Department of Medical Oncology, Addenbrooke's Hospital, Cambridge, UK., Hall M; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK., Banerjee S; Gynaecological Unit, The Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, UK., Glasspool RM; Beatson West of Scotland Cancer Centre, Glasgow, UK., Jones R; Velindre Cancer Centre, Wales, UK., Williams S; Birmingham City Hospital, Birmingham, UK., Swart AM; Norwich Medical School, University of East Anglia, Norwich, UK., Stenning S; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK., Parmar M; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK., Kaplan R; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK., Ledermann JA; University College London Cancer Institute, and University College London Hospitals, London, UK.

المصدر: Lancet (London, England) [Lancet] 2019 Dec 07; Vol. 394 (10214), pp. 2084-2095. Date of Electronic Publication: 2019 Nov 29.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma, Ovarian Epithelial/*drug therapy , Fallopian Tube Neoplasms/*drug therapy , Ovarian Neoplasms/*drug therapy , Peritoneal Neoplasms/*drug therapy, Aged ; Asian People ; Carboplatin/administration & dosage ; Carcinoma/drug therapy ; Carcinoma/pathology ; Carcinoma, Ovarian Epithelial/pathology ; Chemotherapy, Adjuvant ; Chemotherapy-Induced Febrile Neutropenia/epidemiology ; Cytoreduction Surgical Procedures ; Fallopian Tube Neoplasms/pathology ; Female ; Gynecologic Surgical Procedures ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Grading ; Neoplasm Staging ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/epidemiology ; Peritoneal Neoplasms/pathology ; Progression-Free Survival ; Proportional Hazards Models ; White People